Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 5:09 AM
Ignite Modification Date: 2025-12-26 @ 4:13 AM
NCT ID: NCT03959527
Description: All adverse events (AE) that occurred between Day -1 to Day 30 are reported, irrespective of causality assessment. Any AE that occurs after the reporting period assessed as possibly related to the investigational treatment should also be reported. For screening failure participants, AEs are reported up until the date the participant was determined to be a screening failure. Beyond that date, only serious or medically relevant protocol-related events will be followed-up.
Frequency Threshold: 3
Time Frame: 30 days (+/- 3 days)
Study: NCT03959527
Study Brief: Zoliflodacin in Uncomplicated Gonorrhoea
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Zoliflodacin Participant in this arm will receive a single dose of zoliflodacin. zoliflodacin: Dose: 3g, oral administration 0 None 0 619 162 619 View
Ceftriaxone and Azithromycin Combination Participant in this arm will receive a single dose of comparators combination (ceftriaxone and azithromycin). ceftriaxone: Dose: 500mg, Intra-Muscular (IM) administration azithromycin: Dose: 1g, oral administration 0 None 0 308 107 308 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Dizziness SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (26.0) View
Injection site pain SYSTEMATIC_ASSESSMENT General disorders MedDRA (26.0) View
Neutrophil count decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA (26.0) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (26.0) View
Neutropenia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (26.0) View
Leukopenia SYSTEMATIC_ASSESSMENT Blood and lymphatic system disorders MedDRA (26.0) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (26.0) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (26.0) View